PALMER H. FUTCHER, M.D.; EDWARD MASSIE, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
That agranulocytosis1, 2 and leukopenia3 may occur during the treatment of hyperthyroidism with propylthiouracil has already been reported. We have utilized this drug in treating hyperthyroidism in a small group of patients and have encountered agranulocytosis in one instance. In order to facilitate the accumulation of statistics on the toxicity of this drug, we are reporting this latter episode. The smallness of our group renders worthless any calculation of the incidence of agranulocytosis due to propylthiouracil based on our data alone.
We have treated 27 patients with 6-n-propylthiouracil2 for periods varying from 13 to 328 days; 26 of the group
FUTCHER PH, MASSIE E. AGRANULOCYTOSIS DUE TO PROPYLTHIOURACIL1. Ann Intern Med. ;32:137–138. doi: 10.7326/0003-4819-32-1-137
Download citation file:
Published: Ann Intern Med. 1950;32(1):137-138.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use